Accurate and fast delivery of key events and news of growing Genexine
Genexine to Present Positive Six Month GX-H9 Phase 2 Interim Data at IMPE
Genexine Inc. (KOSDAQ: 095700), clinical stage biotechnology company developing innovative biologics focused on orphan diseases and immune-oncology, today announced that the company would present EU/KR Phase 2 interim result of GX-H9, a long-acting growth hormone for pediatric growth hormone deficiency (PGHD) at 10th International Meeting of Pediatric Endocrinology (IMPE), Sep 14 – 17, 2017 in Washington D. C. This interim result will include six month annualized height velocities data from 44 patients out of 48 patients (~90%).
IMPE 2017 is an occasion gathering more than 4,000 endocrinologists and relevant companies from 100 countries. For the occasion, chairman Young Chul Sung, vice president Jungwon Woo, and top executives from Handok will attend the conference to discuss business cooperation with global pharmaceutical companies and investors.
Event: 10th International Meeting of Pediatric Endocrinology
Date: September 16th 12:00 – 13:00
Location: Marriott Wardman Park, Washington D.C.
▶ About Genexine:
Genexine, Inc., listed on KOSDAQ (095700) since 2009, is a leading biotherapeutics company focused on orphan diseases and immuno-oncology. Genexine has robust pipelines in clinical and pre-clinical stages based on long-acting Fc fusion technology and therapeutic DNA technology. Three Phase 2 and four Phase 1 clinical trials are currently ongoing in 2017. GX-H9, a long-acting human growth hormone for PGHD, currently in multinational phase 2 trial and phase 2 study for AGHD was completed at the end of last year. Genexine has entered into a manufacturing agreement with a global CMO company, CMC biologics for preparing phase 3 trial. Genexine is located in Pangyo Techno Valley near Seoul.
HANDOK, a leading innovation-driven pharmaceutical/health-care company in Korea, develops, manufactures and distributes healthcare solutions to improve the health and quality of human life. Handok has a core business focus in diabetes, cardiovascular, muscular skeletal, psychoneurotic disease, human vaccines, medical devices, diagnostics and consumer health. Handok, founded in 1954, grew as a joint venture with Hoechst/Aventis/Sanofi from 1964 to 2012. Handok has also established strategic collaborations in several areas with multiple multinational pharmaceutical companies.